Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mecbotamab vedotin - BioAtla

Next Previous
Drug Profile

Mecbotamab vedotin - BioAtla

Alternative Names: BA-3011 - BioAtla; CAB-Axl antibody-drug conjugates - BioAtla; CAB-AXL-ADC - BioAtla; CAB-AXL-ADC - Himalaya Therapeutics; HTBA-3011; Mecbotamab - BioAtla

Latest Information Update: 21 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioAtla
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Ovarian cancer; Soft tissue sarcoma
  • Phase I/II Solid tumours

Most Recent Events

  • 07 Nov 2025 Adverse events and efficacy data from a phase-II trial in Soft tissue sarcoma by BioAtla
  • 09 Jul 2025 BioAtla completes phase-II clinical trials in Non-small cell lung cancer (Monotherapy, Combination therapy, Second-line therapy or greater, Metastatic disease, In adults, In the elderly) in Spain, Greece, Italy, Germany, USA, Hong Kong, Poland, Spain and Taiwan (Parenteral) (NCT04681131)
  • 06 May 2025 Efficacy data from a phase-II trial in Non-small cell lung cancer released by BioAtla

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top